Toronto Star ... for failing to weed out clients who are so weak or unskilled as to pose a danger to themselves — such as Jesse Easterling, who nearly died on the mountain in 2009 as the result of an overdose of the “climber's little helper,” the steroid ... and more »
EON: Enhanced Online News (press release) REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle-East and Asia, and in ...
MarketWatch (press release) In the study, presented by Katja Weisel, M.D., Department of Medicine, University Hospital Tubingen, Tubingen, Germany, 455 patients were randomized to receive either pomalidomide plus low-dose dexamethasone (n=302) or high-dose dexamethasone ... and more »
MarketWatch The trial evaluated use of oral pomalidomide plus low-dose dexamethasone (n=302) compared with high-dose dexamethasone (n=153) in patients with relapsed and refractory multiple myeloma; according to the protocol, all patients were to have been ...
The Myeloma Beacon In particular, 67 percent had received a Velcade-based regimen, 31 percent thalidomide (Thalomid), and 19 percent Revlimid; additionally, 31 percent were treated with Revlimid, Velcade, and dexamethasone (Decadron) combination therapy. Results ...
